Merck & Company Inc (MRK)vsStryker Corporation (SYK)
MRK
Merck & Company Inc
$119.37
+2.58%
HEALTHCARE · Cap: $287.71B
SYK
Stryker Corporation
$327.65
-0.26%
HEALTHCARE · Cap: $125.72B
Smart Verdict
WallStSmart Research — data-driven comparison
Merck & Company Inc generates 159% more annual revenue ($65.01B vs $25.12B). MRK leads profitability with a 28.1% profit margin vs 12.9%. SYK appears more attractively valued with a PEG of 1.60. SYK earns a higher WallStSmart Score of 65/100 (C+).
MRK
Buy59
out of 100
Grade: C
SYK
Buy65
out of 100
Grade: C+
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-141.2%
Fair Value
$49.50
Current Price
$119.37
$69.87 premium
Margin of Safety
+16.8%
Fair Value
$393.59
Current Price
$327.65
$65.94 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Every $100 of equity generates 37 in profit
Strong operational efficiency at 32.8%
Keeps 28 of every $100 in revenue as profit
Attractively priced relative to earnings
Generating 1.8B in free cash flow
Earnings expanding 55.9% YoY
Large-cap with strong market position
Strong operational efficiency at 27.2%
Generating 1.9B in free cash flow
Areas to Watch
Weak financial health signals
Expensive relative to growth rate
Earnings declined 19.3%
Expensive relative to growth rate
Premium valuation, high expectations priced in
Weak financial health signals
Comparative Analysis Report
WallStSmart ResearchBull Case : MRK
The strongest argument for MRK centers on Market Cap, Return on Equity, Operating Margin. Profitability is solid with margins at 28.1% and operating margin at 32.8%.
Bull Case : SYK
The strongest argument for SYK centers on EPS Growth, Market Cap, Operating Margin. Revenue growth of 11.4% demonstrates continued momentum.
Bear Case : MRK
The primary concerns for MRK are Piotroski F-Score, PEG Ratio, EPS Growth.
Bear Case : SYK
The primary concerns for SYK are PEG Ratio, P/E Ratio, Piotroski F-Score.
Key Dynamics to Monitor
SYK carries more volatility with a beta of 0.87 — expect wider price swings.
SYK is growing revenue faster at 11.4% — sustainability is the question.
SYK generates stronger free cash flow (1.9B), providing more financial flexibility.
Monitor DRUG MANUFACTURERS - GENERAL industry trends, competitive dynamics, and regulatory changes.
Bottom Line
SYK scores higher overall (65/100 vs 59/100) and 11.4% revenue growth. Both earn "Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Merck & Company Inc
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Merck & Co. is an American multinational pharmaceutical company headquartered in Kenilworth, New Jersey. It is named after the Merck family, which set up Merck Group in Germany in 1668.
Visit Website →Stryker Corporation
HEALTHCARE · MEDICAL DEVICES · USA
Stryker Corporation is an American multinational medical technologies corporation based in Kalamazoo, Michigan. Stryker's products include implants used in joint replacement and trauma surgeries; surgical equipment and surgical navigation systems; endoscopic and communications systems; patient handling and emergency medical equipment; neurosurgical, neurovascular and spinal devices; as well as other medical device products used in a variety of medical specialties.
Visit Website →Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?